Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 3/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 5/20 | 0.53 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.53 |
| ▸ | OXTR | P30559 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.50 |
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
| ▸ | NPY2R | P49146 | 1/20 | 0.50 |
| ▸ | NPY4R | P50391 | 1/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.50 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25845603 | 0.94 | NTSR1 (0.54) | NTSR1NTSR2OXTRSLC6A2NPY2R | |
| SCHEMBL25846293 | 0.94 | NTSR1 (0.54) | NTSR1NTSR2OXTRSLC6A2NPY2R | |
| SCHEMBL25845887 | 0.93 | OPRD1 (0.56) | NTSR1NTSR2SLC6A2CALCRLF2 | |
| SCHEMBL25845492 | 0.90 | NTSR1 (0.54) | NTSR1NTSR2OXTRSLC6A2NPY1R | |
| SCHEMBL25845490 | 0.90 | SLC6A2 (0.55) | AGTR2AGTR1NTSR1NTSR2OXTR | |
| SCHEMBL25845686 | 0.86 | NMBR (0.58) | NPY1RNPY2RNPY4RNPY5RF2 | |
| SCHEMBL14930600 | 0.86 | NMBR (0.58) | NPY1RNPY2RNPY4RNPY5RF2 | |
| SCHEMBL14930601 | 0.86 | NMBR (0.58) | NPY1RNPY2RNPY4RNPY5RF2 | |
| SCHEMBL31233911 | 0.82 | SLC6A2 (0.63) | AGTR2AGTR1NTSR1NTSR2SLC6A2 | |
| SCHEMBL31233798 | 0.82 | SLC6A2 (0.63) | AGTR2AGTR1NTSR1NTSR2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116404-A1 | TARGETED NON-INVASIVE IMAGING PROBES OF EGFR EXPRESSING CELLS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116404-A1 | TARGETED NON-INVASIVE IMAGING PROBES OF EGFR EXPRESSING CELLS | EGFR, ERBB2, ERBB3 | AGTR2 1365/4885AGTR1 1125/4885NTSR1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.